Barclays Raises Charles River Labs to Overweight, Downgrades Medpace to Underweight
ByAinvest
Thursday, Oct 2, 2025 9:42 am ET1min read
CRL--
Barclays has upgraded Charles River Laboratories to Overweight and downgraded Medpace to Underweight in its Q3 US life science tools and diagnostics preview. The bank expects stable industry end markets to improve incrementally, with pharma bottom and conservative estimates suggesting the latest round of cuts may be the last. Valuation remains well below trough levels for Charles River, while Medpace's premium valuation over peers looks stretched. Barclays maintains a Neutral sector view, arguing that the recovery will mirror pharma – slow and steady.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet